Flow cytometry staining buffer 1x

Manufactured by R&D Systems

Sourced in United States

Flow Cytometry Staining Buffer (1X) is a buffered solution designed for use in flow cytometry applications. It is formulated to maintain the integrity of cells and facilitate the staining process. The buffer helps to preserve the cellular structure and antigen expression during sample preparation and analysis.

Automatically generated - may contain errors

Lab products found in correlation

Ifn γ, by Merck Group (1 mentions) 5 fluorouracil 5 fu, by Merck Group (1 mentions) Oxaliplatin, by Merck Group (1 mentions) Taxol, by Merck Group (1 mentions) Ve 822, by Selleck Chemicals (1 mentions) Erlotinib, by LC Laboratories (1 mentions) Ku 60019, by LC Laboratories (1 mentions) Irinotecan, by LC Laboratories (1 mentions) Facscalibur flow cytometer, by BD (1 mentions) Propidium iodide, by Merck Group (1 mentions) Facsdiva software, by BD (1 mentions) Neuraminidase, by Merck Group (1 mentions)

Spelling variants of this product

Flow cytometry staining buffer (22 citations) Flow cytometry buffer (7 citations) Staining buffer (3 citations)

3 protocols using flow cytometry staining buffer 1x

Drug Concentration Optimization for Cell Studies

Check if the same lab product or an alternative is used in the 5 most similar protocols

Stock concentrations of the compounds were prepared in Dimethyl sulfoxide (DMSO) and stored at −20°C. SM-7368 (481411-5mg), CPT (C9911-250MG), KU60019 (SML1416-5MG), irinotecan (IRI) (SKU-I1406-50MG), and VE-822 (1232416-25-9) were purchased from Sigma-Aldrich (St. Louis, MO). AZD7762 (Enzo, ENZ-CHM185-0005) from ENZO. Flow Cytometry Staining Buffer (1X) (Cat# FC001), Mouse PE-IgG2a (R&D IC003p), and Human HLA Class I (MHC I) Phycoerythrin mAb (Clone W6/32) were purchased from R&D Systems. Unless indicated otherwise, the drugs were used at the following concentrations: CPT 0.5-1 µM; SM-7368 5 µM; irinotecan 25 µg/ml; VP-16 (Etoposide, LC laboratories) 25 µM; γ-IFN (Sigma) 50 ng/ml; VE822 (Selleckchem) 100 nM; AZD7762 100 nM, KU60019 at 1 µM; erlotinib (LC laboratories) 20 µM; oxaliplatin (Sigma) 10 µM; taxol (Sigma) 50 nM; 5-Fluorouracil (5-FU, Sigma) 10 µM. For experiments in this study, single drug concentrations were pre-determined based on the length of treatment (24–48 h) that induced the expression of target proteins without visibly killing the treated cells.

Hassan M., Trung V., Bedi D., Shaddox S., Gunturu D., Yates C., Datta P, & Samuel T. (2022). Interference with pathways activated by topoisomerase inhibition alters the surface expression of PD-L1 and MHC I in colon cancer cells. Oncology Letters, 25(1), 41.

+ Open protocol

+ Expand

Cell Viability Assay with Cyanoacrylates

Check if the same lab product or an alternative is used in the 5 most similar protocols

The confluent cultures were trypsinized, centrifuged and counted under a hemocytometer. Aliquots of 3 x 10⁵ cells were seeded onto UCA, 1-PCA and 4-PCA wells (3 replicates per CA) and immediately filled with 2 ml of complete DMEM. Cells grown in the absence of cyanoacrylates were used as a control. The plates were incubated under a controlled atmosphere for 24 h. Following this, the medium from each well was collected, and cells were harvested by trypsinization. The detached cells and culture medium were mixed, centrifuged (200 g for 7 min) and resuspended in 2 ml of flow cytometry staining buffer 1X (R&D Systems Inc., Minneapolis, MN, USA). The cell suspension was centrifuged again under the same conditions. Pelleted cells were resuspended in 400 μl of staining buffer and transferred to flow cytometry tubes, and 10 μl of propidium iodide (Sigma-Aldrich, St. Louis, MO, USA) was added to each tube. The rate of cell viability was determined using an argon laser (480 nm) FACSCalibur flow cytometer (BD Becton, Dickinson and Company, Durham, NC, USA), and data were analyzed using Cyflogic software (CyFlo. Ltd., Finland).

Pascual G., Sotomayor S., Rodríguez M., Pérez-Köhler B., Kühnhardt A., Fernández-Gutiérrez M., San Román J, & Bellón J.M. (2016). Cytotoxicity of Cyanoacrylate-Based Tissue Adhesives and Short-Term Preclinical In Vivo Biocompatibility in Abdominal Hernia Repair. PLoS ONE, 11(6), e0157920.

+ Open protocol

+ Expand

Quantifying Cholangiocyte Sialic Acid Levels

Check if the same lab product or an alternative is used in the 5 most similar protocols

Primary adult cholangiocytes were cultured to 80% confluence on a 10 cm plate on collagen at 37°C. Cells were trypsinized, suspended in serum-free BEC medium and incubated with or without 0.1 U/ml (Sigma) neuraminidase in serum-free BEC medium for 2.5 h. Cells were washed with BEC medium containing 10% FBS and were resuspended in Flow Cytometry Staining Buffer (1X) (R&D Systems, Minneapolis, MN, USA) supplemented with 1% FBS. They were incubated with 1 μg/ml of FITC-soybean agglutinin (SBA) lectin (Vector Laboratories, Burlingame, CA, USA) for 30 min. Cells were then washed and resuspended in FACS buffer and analyzed for lectin binding affinity by performing flow cytometry analysis on an LSR II equipped with FACS DiVA software (version 6.1.1; BD). Measurement in the absence of lectins was performed as a negative control and at least 1 × 10⁴ cells were analyzed for each sample. Data were analyzed using FlowJo software (version 10; FLOWJO, LLC). The data were manually gated in FlowJo and then Flow SOM was performed using the plugin installed in the software (18 (link)). A minimal spanning tree was constructed to visualize the expression of FITC.

Khandekar G., Llewellyn J., Kriegermeier A., Waisbourd-Zinman O., Johnson N., Du Y., Giwa R., Liu X., Kisseleva T., Russo P.A., Theise N.D, & Wells R.G. (2019). Coordinated development of the mouse extrahepatic bile duct: implications for neonatal susceptibility to biliary injury. Journal of hepatology, 72(1), 135-145.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!